Engineering Injectable Microporous Hydrogels for Diabetic Wound Repair
Engineering Injectable Microporous Hydrogels for Diabetic Wound Repair
批准号:
10161123
负责人:
Donald Richieri Griffin
金额:
$14.69万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-07-01 至 2021-06-30
关键词:
AddressAmino Acid SubstitutionAmino AcidsBiocompatible MaterialsBrainCaliberCell LineCellsCharacteristicsCrosslinkerDataDermalDiabetic mouseEngineeringEnsureExperimental DesignsExposure toFormulationFundingGelGenerationsGeometryGoalsGrowthHeparinHistologyHydrogelsImmuneImmune responseImmunofluorescence ImmunologicIn SituIn VitroIndividualInflammationInjectableInstructionInterstitial CollagenaseInvestigationIslandLibrariesMaintenanceMediatingMicrofluidicsMicroscopicNanoporousNatural regenerationPeptide HydrolasesPeptidesPhysiologicalPorosityPropertyProteolysisPublishingRegenerative responseResearch ProposalsResistanceResolutionSkinSplint DeviceTestingThickTimeTimeLineTissuesWound modelsangiogenesisbasecollagenase 1designdiabeticdiabetic ulcerdiabetic wound healingexperimental studyhealingimmunoregulationimprovedin vivokeratinocytemacrophagemigrationneurogenesisnon-diabeticnovelparticleprematureprotein aminoacid sequenceresponsescaffoldtranslational impactwoundwound closurewound environmentwound healingwound treatment
中文摘要
项目总结
在这项提案中,我们的目标是设计一种生物材料支架,通过改进
我们发明的水凝胶生物材料的新亚类称为微孔退火颗粒凝胶或MAP凝胶。地图
凝胶由使用微流控生成并原位组装成的微观球形构建块组成
形成稳定的地图脚手架。MAP支架已经被证明可以通过一种
减少伤口炎症,促进细胞/组织整合。我们专注于
材料改进以应对糖尿病创面材料治疗的三个已知困难:异常
高免疫活性,增加了蛋白酶浓度,减少了新组织的生成。具体来说,我们有
确定了我们可以独立调整以进行指导性优化的三个映射属性:孔道几何(已知
免疫调节参数)、可降解性(过早的材料降解会导致气孔介导的损失效应),以及
非均相肝素“微岛”(我们开发的一种新的基于材料的策略来改进支架内
血管生成)。我们假设,单独调查和优化每种属性将加速糖尿病
伤口闭合,优化的性能可以协同结合。
我们将使用以下表征工作流程评估和优化每种材料特性:体外特性
量化(属性相关)、体外细胞反应(存活、增殖和迁移)、体内免疫
反应(FACS分析)、体内材料降解(组织学分析)和体内组织愈合/再生
(免疫组织学分析)。我们的研究集中在糖尿病伤口环境中,通过使用真皮细胞系
体外和糖尿病小鼠(db/db)夹板伤口愈合模型。我们方法的每个目标都孤立了一个人
材料属性,以简化调查。例如,使用单个水凝胶来研究孔几何形状的影响。
配方和水凝胶配方影响使用单一孔道几何形状(采用恒定配方和孔道几何形状
来自我们成功的非糖尿病研究)。如果成功,这个项目将提供对组织反应的更好的理解
一种新的生物材料(MAP支架),并产生一种廉价而有效的支架治疗选项
加速糖尿病伤口的闭合。
英文摘要
PROJECT SUMMARY
In this proposal, we aim to engineer a biomaterial scaffold to accelerate diabetic wound closure by improving upon a
new sub-class of hydrogel biomaterials we have invented called Microporous Annealed Particle gel or MAP gel. MAP
gels are composed of microscopic spherical building blocks made using microfluidic generation and assembled in situ to
form a stable MAP scaffold. MAP scaffolds have been shown to improve tissue healing in both skin and brain through a
porosity-dependent reduction in wound inflammation and promotion of cell/tissue integration. We are focusing on
material improvements to counter three known difficulties for material-based treatment of diabetic wounds: abnormally
high immune activity, increased protease concentrations, and diminished new tissue generation. Specifically, we have
identified three MAP properties that we can independently modulate for instructive optimization: pore geometry (known
immunomodulatory parameter), degradability (premature material degradation results in loss pore-mediated effects), and
heterogeneous heparin “micro-islands” (a novel material-based strategy we have developed to improve intra-scaffold
angiogenesis). We hypothesize that investigating and optimizing each property individually will accelerate diabetic
wound closure and that the optimized properties can be combined synergistically.
We will evaluate and optimize each material property using the following characterization workflow: in vitro property
quantification (property-dependent), in vitro cell response (survival, proliferation, and migration), in vivo immune
response (analysis by FACS), in vivo material degradation (analysis by histology), and in vivo tissue healing/regeneration
(analysis by immunohistology). Our studies focus on the diabetic wound environment through use of dermal cell lines in
vitro and a diabetic mouse (db/db) splinted wound healing model. Each Aim of our approach isolates an individual
material property to simplify the investigation. For example, pore geometry impact is investigated using a single hydrogel
formulation and hydrogel formulation impact uses a single pore geometry (constant formulation and pore geometry taken
from our successful non-diabetic studies). If successful, this project will provide a better understanding of tissue response
to a new class of biomaterial (MAP scaffold) and produce an inexpensive and effective scaffold treatment option for
accelerating diabetic wound closure.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Spatially heterogeneous epidermal growth factor release from microporous annealed particle (MAP) hydrogel for improved wound closure.
微孔退火颗粒 (MAP) 水凝胶释放空间异质表皮生长因子,以改善伤口闭合。
DOI:
10.1039/d1tb00715g
发表时间:
2021-09-15
期刊:
Journal of materials chemistry. B
影响因子:
--
作者:
[Pruett L, Ellis R, McDermott M, Roosa C, Griffin D]
通讯作者:
Griffin D
DOI:
10.1021/acsbiomaterials.0c01580
发表时间:
2021-02-08
期刊:
ACS biomaterials science & engineering
影响因子:
5.8
作者:
[Pfaff BN, Pruett LJ, Cornell NJ, de Rutte J, Di Carlo D, Highley CB, Griffin DR]
通讯作者:
Griffin DR
Engineering Injectable Microporous Hydrogels for Diabetic Wound Repair
-
批准号:10460610
-
项目类别:
-
资助金额:$64.44万
-
财政年份:2021
-
负责人:Donald Richieri Griffin
-
依托单位:
Engineering Injectable Microporous Hydrogels for Diabetic Wound Repair
-
批准号:10297936
-
项目类别:
-
资助金额:$64.44万
-
财政年份:2021
-
负责人:Donald Richieri Griffin
-
依托单位:
Engineering Injectable Microporous Hydrogels for Diabetic Wound Repair
-
批准号:10657614
-
项目类别:
-
资助金额:$63.04万
-
财政年份:2021
-
负责人:Donald Richieri Griffin
-
依托单位:
VEGF Gradients in Porous Hydrogels for Therapeutic Angiogenesis
-
批准号:8992266
-
项目类别:
-
资助金额:$6.0万
-
财政年份:2015
-
负责人:Donald Richieri Griffin
-
依托单位:
海外基金